We reported last December that the Committee for Medicinal Products for Human Use had adopted a positive opinion and had recommended marketing authorization for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent prostate cancer.
According to a media release from Ferring Pharmaceuticals earlier today, the European Union has now finalized approval of degarelix for clinical use in Europe.
Filed under: Drugs in development | Tagged: approval, Degarelix |
Leave a Reply